Clinical Trial Update: A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update evaluating subcutaneous risankizumab induction for moderately to severely active Crohn's disease, focusing on adverse events and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• SKYRIZI (risankizumab-rzaa)

Snippet

Sponsor: AbbVie | Conditions: Crohn's Disease | Phase 3 | Status: ACTIVE_NOT_RECRUITING